116 related articles for article (PubMed ID: 34905961)
1. Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries.
Iida O; Ohki T; Soga Y; Suematsu N; Nakama T; Yamaoka T; Tobita K; Ichihashi S
J Endovasc Ther; 2022 Dec; 29(6):855-865. PubMed ID: 34905961
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery.
Ohki T; Kichikawa K; Yokoi H; Iida O; Yamaoka T; Maeda K; Kanaoka Y
J Vasc Surg; 2021 Dec; 74(6):1958-1967.e2. PubMed ID: 34182032
[TBL] [Abstract][Full Text] [Related]
3. Five-year outcomes of the GORE VIABAHN Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study.
Iida O; Ohki T; Soga Y; Suematsu N; Nakama T; Yamaoka T; Tobita K; Ichihashi S
Vasc Med; 2024 Mar; ():1358863X241233528. PubMed ID: 38544413
[No Abstract] [Full Text] [Related]
4. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions.
Ohki T; Kichikawa K; Yokoi H; Uematsu M; Yamaoka T; Maeda K; Kanaoka Y
J Vasc Surg; 2017 Jul; 66(1):130-142.e1. PubMed ID: 28400218
[TBL] [Abstract][Full Text] [Related]
6. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial.
Zeller T; Peeters P; Bosiers M; Lammer J; Brechtel K; Scheinert D; Rastan A; Noory E; Beschorner U
J Endovasc Ther; 2014 Dec; 21(6):765-74. PubMed ID: 25453876
[TBL] [Abstract][Full Text] [Related]
7. Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial.
Bosiers M; Deloose K; Callaert J; Verbist J; Hendriks J; Lauwers P; Schroë H; Lansink W; Scheinert D; Schmidt A; Zeller T; Beschorner U; Noory E; Torsello G; Austermann M; Wauters J
J Cardiovasc Surg (Torino); 2020 Oct; 61(5):617-625. PubMed ID: 33231029
[TBL] [Abstract][Full Text] [Related]
8. Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial.
Böhme T; Noory E; Brechtel K; Scheinert D; Bosiers M; Beschorner U; Zeller T
J Endovasc Ther; 2021 Apr; 28(2):222-228. PubMed ID: 33044119
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis.
Mohr PJ; Oyama JK; Luu JT; Stinis CT
Cardiovasc Revasc Med; 2015 Dec; 16(8):465-8. PubMed ID: 26483319
[TBL] [Abstract][Full Text] [Related]
10. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.
Geraghty PJ; Mewissen MW; Jaff MR; Ansel GM;
J Vasc Surg; 2013 Aug; 58(2):386-95.e4. PubMed ID: 23676191
[TBL] [Abstract][Full Text] [Related]
11. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial.
Bosiers M; Deloose K; Callaert J; Verbist J; Hendriks J; Lauwers P; Schroë H; Lansink W; Scheinert D; Schmidt A; Zeller T; Beschorner U; Noory E; Torsello G; Austermann M; Peeters P
J Endovasc Ther; 2015 Feb; 22(1):1-10. PubMed ID: 25775672
[TBL] [Abstract][Full Text] [Related]
12. Use of the Gore Tigris Vascular Stent in Advanced Femoropopliteal Peripheral Arterial Disease.
Lucatelli P; Cini M; Tommasino G; Benvenuti A; Guaccio G; Bascetta S; Neri E; Ricci C
J Vasc Interv Radiol; 2018 May; 29(5):614-622. PubMed ID: 29452721
[TBL] [Abstract][Full Text] [Related]
13. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the EPIC™ nitinol vascular stent system for the treatment of lesions located in the superficial femoral artery: prospective and multicentric trial.
Nasser F; Kambara A; Abath C; Cavalcanti D; Barros I; Pires N; Rivera M; Neser A; Ingrund J; Burihan M; Silveira P; Galego G; Bortoluzzi C; Franklin R; Bosiers M; Deloose K; Razuk A; Caffaro R; Karakhanian WK; Park J; Lopes C; Pinto D; Bez L; Lopes R; Mourão A; Kleinsorge G
J Cardiovasc Surg (Torino); 2017 Jun; 58(3):409-415. PubMed ID: 25731858
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
16. Medium-Term Outcomes of Treatment with a VIABAHN VBX Covered Stent for Aortoiliac Occlusive Lesions in Patients with Peripheral Artery Disease.
Maeda K; Kobayashi T; Emura S; Okazaki T; Mochizuki S; Sato T; Taniguchi M; Futagami D; Inoue R; Tomota M; Hiraoka T; Shimonaga T; Tachibana H; Shimizu H; Takahashi S
Ann Vasc Surg; 2024 Aug; 105():201-208. PubMed ID: 38604500
[TBL] [Abstract][Full Text] [Related]
17. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial.
Saxon RR; Chervu A; Jones PA; Bajwa TK; Gable DR; Soukas PA; Begg RJ; Adams JG; Ansel GM; Schneider DB; Eichler CM; Rush MJ
J Vasc Interv Radiol; 2013 Feb; 24(2):165-73; quiz 174. PubMed ID: 23369553
[TBL] [Abstract][Full Text] [Related]
18. Endovascular Treatment of Severely Calcified Femoropopliteal Lesions Using the "Pave-and-Crack" Technique: Technical Description and 12-Month Results.
Dias-Neto M; Matschuck M; Bausback Y; Banning-Eichenseher U; Steiner S; Branzan D; Staab H; Varcoe RL; Scheinert D; Schmidt A
J Endovasc Ther; 2018 Jun; 25(3):334-342. PubMed ID: 29557221
[TBL] [Abstract][Full Text] [Related]
19. The association of statin therapy with the primary patency of femoral and popliteal artery stents.
de Grijs D; Teixeira P; Katz S
J Vasc Surg; 2018 May; 67(5):1472-1479. PubMed ID: 29224939
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
McQuade K; Gable D; Hohman S; Pearl G; Theune B
J Vasc Surg; 2009 Jan; 49(1):109-15, 116.e1-9; discussion 116. PubMed ID: 19028055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
